RA Capital Management,
$11.5B 13F equity value
101 Holdings
Quarter ended June 30, 2026
The latest 13F on file for RA Capital Management, covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| ASND | ASCENDIS PHARMA A/S | 10,281,496 | $2.7B | 23.8% |
| PBLS | PARABILIS MEDICINES INC | 28,933,371 | $792M | 6.9% |
| RYTM | RHYTHM PHARMACEUTICALS INC | 6,666,837 | $740M | 6.4% |
| PCVX | VAXCYTE INC | 11,474,599 | $667M | 5.8% |
| SION | SIONNA THERAPEUTICS INC | 9,905,045 | $436M | 3.8% |
| TYRA | TYRA BIOSCIENCES INC | 12,198,625 | $390M | 3.4% |
| EWTX | EDGEWISE THERAPEUTICS INC | 8,392,730 | $341M | 3.0% |
| NAMS | NEWAMSTERDAM PHARMA CO NV | 9,550,191 | $324M | 2.8% |
| COAG | HEMAB THERAPEUTICS HOLDINGS | 7,808,627 | $287M | 2.5% |
| SEPN | SEPTERNA INC | 6,995,858 | $234M | 2.0% |
Track RA Capital Management,'s 13F portfolio: $11.5B in reported holdings, 101 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}